Talking With Educators

If your child has PI, it's important that other adults he or she comes in contact with—teachers, school nurses, and administrators—understand the condition and its treatment.

Share These Important Points to Help Educators Understand

  • Explain that PI stands for "primary immmunodeficiency disease," a genetic condition that makes your child susceptible to illness and infections.
  • Reassure your child's educators that your child poses no risk to other children. PI is not contagious and cannot be spread to other children or adults.
  • Let educators know that your child can participate in classroom and playground activities.
  • Describe how common germs can be especially harmful—even life-threatening—to your child's health.
  • Request a 504 plan, a plan that you and the school develop to ensure your child receives accommodations that will ensure academic success and access to the learning environment.

Ask Educators to Help Minimize Your Child's Exposure to Germs

  • Ask educators to encourage children to stay home from school when they are sick.
  • Request that if classmates do come to school sick that they be sent to the nurse's office or separated as much as possible from your child.
  • Appeal to the educator to reinforce good hygiene and encourage children to wash their hands after sneezing, blowing their noses, or using the restroom.

Alert Educators to Recognize Potential Problems

  • Ask educators to contact you if your child appears overly tired, feverish, chilled, or exhibits symptoms including cough, congestion, runny nose, earache, difficulty breathing or headache.
  • Communicate that your child's treatment experience may result in side effects, such as fatigue, headache, or swelling at infusion site.

Talking With Family & Friends

It's important for the entire family—especially siblings—to know about PI. They need to understand that your child can live a normal life with proper treatment.

With siblings, make them aware that having PI makes their brother or sister more susceptible to getting sick. If they have friends with colds or the flu, make it a point not to bring them home.

Tell your child's friends and their parents that PI is not contagious and cannot be spread to other children or adults. Let them know that having PI does not necessarily limit a child's activities.

Important Safety Information
Expand

Important Safety Information

WARNING: Thrombosis (blood clots) can occur with immune globulin products, including Hizentra. Risk factors can include: advanced age, prolonged immobilization, a history of blood clotting or hyperviscosity (blood thickness), use of estrogens, installed vascular catheters, and cardiovascular risk factors.

If you are at high risk of blood clots, your doctor will prescribe Hizentra at the minimum dose and infusion rate practicable and will monitor for signs of clotting events and hyperviscosity. Always drink sufficient fluids before infusing Hizentra.

See your doctor for a full explanation, and the full prescribing information for complete boxed warning.

Hizentra®, Immune Globulin Subcutaneous (Human), 20% Liquid, is a prescription medicine used to treat:

  • Primary immune deficiency (PI) in patients 2 years and older
  • Chronic inflammatory demyelinating polyneuropathy (CIDP) in adults

Treatment with Hizentra might not be possible if your doctor determines you have hyperprolinemia (too much proline in the blood), or are IgA-deficient with antibodies to IgA and a history of hypersensitivity. Tell your doctor if you have previously had a severe allergic reaction (including anaphylaxis) to the administration of human immune globulin. Tell your doctor right away or go to the emergency room if you have hives, trouble breathing, wheezing, dizziness, or fainting. These could be signs of a bad allergic reaction.

Inform your doctor of any medications you are taking, as well as any medical conditions you may have had, especially if you have a history of diseases related to the heart or blood vessels, or have been immobile for some time. Inform your physician if you are pregnant or nursing, or plan to become pregnant.

Infuse Hizentra under your skin only; do not inject into a blood vessel. Self-administer Hizentra only after having been taught to do so by your doctor or other healthcare professional, and having received dosing instructions for treating your condition.

Immediately report to your physician any of the following symptoms, which could be signs of serious adverse reactions to Hizentra:

  • Reduced urination, sudden weight gain, or swelling in your legs (possible signs of a kidney problem).
  • Pain and/or swelling or discoloration of an arm or leg, unexplained shortness of breath, chest pain or discomfort that worsens on deep breathing, unexplained rapid pulse, or numbness/weakness on one side of the body (possible signs of a blood clot).
  • Bad headache with nausea; vomiting; stiff neck; fever; and sensitivity to light (possible signs of meningitis).
  • Brown or red urine; rapid heart rate; yellowing of the skin or eyes; chest pains or breathing trouble; fever over 100°F (possible symptoms of other conditions that require prompt treatment).

Hizentra is made from human blood. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent and its variant (vCJD), cannot be completely eliminated.

The most common side effects in the clinical trials for Hizentra include redness, swelling, itching, and/or bruising at the infusion site; headache; chest, joint or back pain; diarrhea; tiredness; cough; rash; itching; fever, nausea, and vomiting. These are not the only side effects possible. Tell your doctor about any side effect that bothers you or does not go away.

Before receiving any vaccine, tell immunizing physician if you have had recent therapy with Hizentra, as effectiveness of the vaccine could be compromised.

Please see full prescribing information for Hizentra, including boxed warning and the patient product information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Collapse
Patient/Caregiver PI Learning Center Talking With Educators, Family, and Friends
CSL Behring
Hizentra is manufactured by CSL Behring AG and distributed by CSL Behring LLC.
Hizentra® and MyHizentra® are registered trademarks of CSL Behring AG.
Biotherapies for Life® is a registered trademark of CSL Behring LLC.
CSL Behring AssuranceSM, IgIQSM, and Premier StartSM are service marks of CSL Behring LLC.
Voice2Voice® is a registered trademark of CSL Behring GmbH.
© 2018 CSL Behring LLC. The product information presented on this site is intended for US residents only. HIZ-0316-MAR18